|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Four out of five ROS1 rearranged patients were female, never smokers and with adenocarcinoma histology.
|
26783962 |
2016 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
HER2 mutations were detected in 29 of 572(5.1%) specimens from a selected population of EGFR/KRAS/BRAF/ALK/ROS1 negative patients.All of them are adenocarcinomas.
|
29587667 |
2018 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The rearrangements of ALK/ROS1 are correlated with age, smoking status, expressions of TTF1 & napsin A and solid predominant adenocarcinoma subtype.
|
29268402 |
2017 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Patients harboring ROS1 rearrangement were mostly young (8/10), females (7/10) and non-smokers (7/10) with adenocarcinoma (10/10) and acinar pattern.
|
27488371 |
2016 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Interestingly, the overall survival of the 13 ROS1-positive patients with lung cancer from initiation of pemetrexed-based chemotherapy was significantly prolonged when compared with that of 169 pemetrexed-treated patients with EGFR/anaplastic lymphoma kinase/ROS1-negative adenocarcinoma (p = 0.01).
|
27575422 |
2017 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
ROS1 rearrangement is most often identified in never-smokers with adenocarcinoma and EGFR and ALK receptor tyrosine kinase gene (ALK) wild type.
|
29883837 |
2018 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
ROS1-rearranged adenocarcinoma exhibited distinct morphological and clinicopathological features.
|
26149475 |
2015 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We diagnosed 9 ROS1-rearranged adenocarcinomas, with both a positive FISH result (51-87% rearranged nuclei) and a positive IHC staining (2+/3+ cytoplasmic staining).
|
24380695 |
2014 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: A case report and literature review.
|
28845578 |
2017 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The aim of this study was to evaluate the adequacy of EBUS-TBNA in providing adequate size specimens for EGFR, ALK and ROS1 genetic mutation analysis in patients with adenocarcinoma or not otherwise specified (NOS) lung cancer.
|
30582673 |
2019 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
It is widely known that ROS1 rearrangement mostly occurs in the adenocarcinoma subtype of non-small-cell lung cancer.
|
30083883 |
2018 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Key new recommendations include ROS1 testing for all adenocarcinoma patients; the inclusion of additional genes (ERBB2, MET, BRAF, KRAS, and RET) for laboratories that perform next-generation sequencing panels; immunohistochemistry as an alternative to fluorescence in situ hybridization for ALK and/or ROS1 testing; use of 5% sensitivity assays for EGFR T790M mutations in patients with secondary resistance to EGFR inhibitors; and the use of cell-free DNA to "rule in" targetable mutations when tissue is limited or hard to obtain.
|
29396253 |
2018 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
ROS1 rearrangement was detected in 3 of 375 samples (0.8 %); all of whom were female, never-smokers, and harbored an adenocarcinoma component.
|
25374304 |
2015 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, the specific histology of adenocarcinoma on cytological materials should promote testing for ROS1 immunohistochemistry.
|
29076659 |
2018 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
ROS1 expression was a worse prognostic factor for overall survival in adenocarcinomas of stage I NSCLC.
|
22915320 |
2013 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
19 tumors were identified with ROS1 rearrangement (3.7% of adenocarcinomas).
|
27708233 |
2016 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In resected stage IIIA-N2 NSCLC patients, ROS1-rearranged cases tended to occur in younger patients with adenocarcinomas.
|
25905642 |
2015 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Through an integrated molecular- and histopathology-based screening system, we performed a screening for fusions of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1, receptor tyrosine kinase (ROS1) in 1,529 lung cancers and identified 44 ALK-fusion-positive and 13 ROS1-fusion-positive adenocarcinomas, including for unidentified fusion partners for ROS1.
|
22327623 |
2012 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
All the ROS1 fusion-positive tumors were adenocarcinomas except 1, which was an adenosquamous carcinoma.
|
23426121 |
2013 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In the subgroup analysis, which was based on tumor subtype, the rate of ROS1 rearrangement and IHC positivity was 2.9% (95% CI 1.9, 4.5) and 0.6% (95% CI 0.3, 1.2) in adenocarcinoma and non-adenocarcinoma, respectively.
|
29874982 |
2018 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Patients with ROS1 gene rearrangements were younger and typically never-smokers, with the tumors all being adenocarcinomas with higher-grade architectural features and focal signet ring morphologic features (two of five).
|
27179848 |
2016 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
ROS1 expression was predominantly found in female adenocarcinoma patients, in patients with low T stages, and in association with TTF1 and napsin expression, and certain histomorphological adenocarcinoma patterns (lepidic, acinar, and solid).
|
24456475 |
2014 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Key new recommendations include ROS1 testing for all adenocarcinoma patients; the inclusion of additional genes (ERBB2, MET, BRAF, KRAS, and RET) for laboratories that perform next-generation sequencing panels; immunohistochemistry as an alternative to fluorescence in situ hybridization for ALK and/or ROS1 testing; use of 5% sensitivity assays for EGFR T790M mutations in patients with secondary resistance to EGFR inhibitors; and the use of cell-free DNA to "rule in" targetable mutations when tissue is limited or hard to obtain.
|
29398453 |
2018 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Strikingly, clinically relevant alterations in the receptor tyrosine kinase (RTK)/Ras signaling pathway including alterations in ALK, ARAF, BRAF, EGFR, FGFR1, FGFR2, KIT, KRAS, MAP2K1, MET, NF1, NF2, NRAS, RAF1, RET, and ROS1 were found in 90 (72%) ACUPs but in only 29 (39%) non-ACUPs (P < .001).
|
26182302 |
2015 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Key new recommendations include ROS1 testing for all adenocarcinoma patients; the inclusion of additional genes ( ERBB2, MET, BRAF, KRAS, and RET) for laboratories that perform next-generation sequencing panels; immunohistochemistry as an alternative to fluorescence in situ hybridization for ALK and/or ROS1 testing; use of 5% sensitivity assays for EGFR T790M mutations in patients with secondary resistance to EGFR inhibitors; and the use of cell-free DNA to "rule in" targetable mutations when tissue is limited or hard to obtain.
|
29355391 |
2018 |